{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:22Z","timestamp":1793212162167,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Ulcerative colitis is chronic inflammatory condition affecting the colon, necessitating remission inducing therapeutic interventions. With the emergence of newer more advanced options, their relative effectiveness remains unclear. This network meta-analysis (NMA) will compare the effectiveness of presently available biologics and small molecules in achieving and maintaining remission among patients of moderate-to-severe ulcerative colitis as part of induction and maintenance therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic search was conducted up to 21st February 2025, including only phase 2b\/3 or 3 randomized controlled trials. The primary outcome was induction and maintenance of clinical remission (Full Mayo Score (FMS)\u2009\u2264\u20092, with no individual subscore\u2009&gt;\u20091). Secondary outcomes assessed were clinical response, endoscopic improvement (Mayo Endoscopic Score (MES)\u2009\u2264\u20091 either with or without friability) and steroid free remission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Across 22 studies (7,683 patients), upadacitinib had the highest likelihood of inducing clinical remission (99.08%), clinical response (97.44%) and endoscopic improvement (99.32%), followed by Infliximab and guselkumab following close by for specific outcomes. In maintenance of clinical remission and endoscopic improvement upadacitinib again ranked highest (95.60%) and (99.46%). Tofacitinib (92.43%) has the highest probability with upadacitinib (87.73%) following behind in achieving steroid free remission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Upadacitinib displayed high efficacy across multiple outcomes in both induction and maintenance therapy with Infliximab, guselkumab, and filgotinib following closely behind. For achieving steroid free remission tofacitinib has the highest probability of doing so. Overall small molecules and selective IL-23 inhibitors seems promising alternative to older biologics though additional head-to-head trial are warranted along with more real-world data.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10787-025-01723-z","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T02:24:41Z","timestamp":1744079081000},"page":"2679-2687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative efficacy of pharmacologic interventions in ulcerative colitis: a network meta analysis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6016-9221","authenticated-orcid":false,"given":"Atta Ullah","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Aamir","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"issue":"2","key":"1723_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/JSS.V106.I02","volume":"106","author":"S Balduzzi","year":"2023","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O, Schwarzer G (2023) netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw 106(2):1\u201340. https:\/\/doi.org\/10.18637\/JSS.V106.I02","journal-title":"J Stat Softw"},{"issue":"7","key":"1723_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3390\/PH14070637","volume":"14","author":"I Ben Ghezala","year":"2021","unstructured":"Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M (2021) Small molecule drugs in inflammatory bowel diseases. Pharmaceuticals 14(7):637. https:\/\/doi.org\/10.3390\/PH14070637","journal-title":"Pharmaceuticals"},{"issue":"Supplement_2","key":"1723_CR3","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ECCO-JCC\/JJAE082","volume":"18","author":"B Caron","year":"2024","unstructured":"Caron B, Honap S, Peyrin-Biroulet L (2024) Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies. J Crohn\u2019s Colitis 18(Supplement_2):ii3\u2013ii15. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJAE082","journal-title":"J Crohn\u2019s Colitis"},{"issue":"7","key":"1723_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/14740338.2020.1773430","volume":"19","author":"F D\u2019Amico","year":"2020","unstructured":"D\u2019Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S (2020) Long-term safety of approved biologics for ulcerative colitis. Expert Opin Drug Saf 19(7):807\u2013816. https:\/\/doi.org\/10.1080\/14740338.2020.1773430","journal-title":"Expert Opin Drug Saf"},{"issue":"26","key":"1723_CR5","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/nejmoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE (2023) Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 388(26):2444\u20132455. https:\/\/doi.org\/10.1056\/nejmoa2207940","journal-title":"N Engl J Med"},{"issue":"18","key":"1723_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMRA1102942","volume":"365","author":"S Danese","year":"2011","unstructured":"Danese S, Fiocchi C (2011) Ulcerative colitis. N Engl J Med 365(18):1713\u20131725. https:\/\/doi.org\/10.1056\/NEJMRA1102942","journal-title":"N Engl J Med"},{"issue":"9","key":"1723_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","volume":"12","author":"S Danese","year":"2015","unstructured":"Danese S, Vuitton L, Peyrin-Biroulet L (2015) Biologic agents for IBD: practical insights. Nat Rev Gastroenterol & Hepatol 12(9):537\u2013545. https:\/\/doi.org\/10.1038\/nrgastro.2015.135","journal-title":"Nat Rev Gastroenterol & Hepatol"},{"issue":"2","key":"1723_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S2468-1253(21)00294-6","volume":"7","author":"S Danese","year":"2022","unstructured":"Danese S, Colombel JF, Lukas M, Gisbert JP, D\u2019Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S, Aboo N, Ahmad T, Aldeguer Mante X, Ziady C (2022a) Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol 7(2):118\u2013127. https:\/\/doi.org\/10.1016\/S2468-1253(21)00294-6","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10341","key":"1723_CR9","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, H\u00e9buterne X, D\u2019Haens G, Nakase H, Pan\u00e9s J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Panaccione R (2022b) Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 399(10341):2113\u20132128. https:\/\/doi.org\/10.1016\/S0140-6736(22)00581-5","journal-title":"Lancet"},{"issue":"10","key":"1723_CR10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/J.CROHNS.2012.09.003","volume":"6","author":"A Dignass","year":"2012","unstructured":"Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohn\u2019s Colitis 6(10):965\u2013990. https:\/\/doi.org\/10.1016\/J.CROHNS.2012.09.003","journal-title":"J Crohn\u2019s Colitis"},{"key":"1723_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/TCRM.S55506","volume":"11","author":"R Fausel","year":"2015","unstructured":"Fausel R, Afzali A, Afzali A (2015) Biologics in the management of ulcerative colitis\u2014comparative safety and efficacy of TNF-\u03b1 antagonists. Ther Clin Risk Manag 11:63\u201372. https:\/\/doi.org\/10.2147\/TCRM.S55506","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"1723_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/nejmoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, Van Assche G, Axler J, Kim H-J, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369(8):699\u2013710. https:\/\/doi.org\/10.1056\/nejmoa1215734","journal-title":"N Engl J Med"},{"issue":"10292","key":"1723_CR13","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempi\u0144ski R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Peyrin-Biroulet L (2021) Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet 397(10292):2372\u20132384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00666-8","journal-title":"Lancet"},{"issue":"11","key":"1723_CR14","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/J.MAYOCP.2014.07.002","volume":"89","author":"JD Feuerstein","year":"2014","unstructured":"Feuerstein JD, Cheifetz AS (2014) Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc 89(11):1553\u20131563. https:\/\/doi.org\/10.1016\/J.MAYOCP.2014.07.002","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"1723_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14712598.2020.1697227","volume":"20","author":"J Han\u017eel","year":"2020","unstructured":"Han\u017eel J, D\u2019Haens GR (2020) Anti-interleukin-23 agents for the treatment of ulcerative colitis. Expert Opin Biol Ther 20(4):399\u2013406. https:\/\/doi.org\/10.1080\/14712598.2020.1697227","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"1723_CR16","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00535-017-1326-1","volume":"52","author":"T Hibi","year":"2017","unstructured":"Hibi T, Imai Y, Senoo A, Ohta K, Ukyo Y (2017) Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study- (PURSUIT-J study). J Gastroenterol 52(10):1101\u20131111. https:\/\/doi.org\/10.1007\/s00535-017-1326-1","journal-title":"J Gastroenterol"},{"issue":"11","key":"1723_CR17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/SIM.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558. https:\/\/doi.org\/10.1002\/SIM.1186","journal-title":"Stat Med"},{"issue":"7414","key":"1723_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/BMJ.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ\u202f: Br Med J 327(7414):557. https:\/\/doi.org\/10.1136\/BMJ.327.7414.557","journal-title":"BMJ : Br Med J"},{"issue":"11","key":"1723_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385\/ASSET\/IMAGES\/6FF14_APPENDIX_BOX_5_DIFFERENCES_IN_APPROACH_TO_FITTING_NETWORK_META-ANALYSES.JPG","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JPA, Straus S, Thorlund K, Jansen JP, Mulrow C, Catala-Lopez F, Gotzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385\/ASSET\/IMAGES\/6FF14_APPENDIX_BOX_5_DIFFERENCES_IN_APPROACH_TO_FITTING_NETWORK_META-ANALYSES.JPG","journal-title":"Ann Intern Med"},{"issue":"4","key":"1723_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1684\/ECN.2021.0472","volume":"32","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Kong D, Miao X, Yu X, Wu Z, Liu H, Gong W (2022) Anti-cytokine therapy and small molecule agents for the treatment of inflammatory bowel disease. Eur Cytokine Netw 32(4):73\u201382. https:\/\/doi.org\/10.1684\/ECN.2021.0472","journal-title":"Eur Cytokine Netw"},{"key":"1723_CR21","doi-asserted-by":"crossref","unstructured":"Jiang, X.-L., Cui, H.-F., Gao, J., & Fan, H. (2015). Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis. www.jcge.com","DOI":"10.1097\/MCG.0000000000000319"},{"issue":"5","key":"1723_CR22","first-page":"255","volume":"15","author":"A Kashani","year":"2019","unstructured":"Kashani A, Schwartz DA (2019) The expanding role of anti\u2013IL-12 and\/or anti\u2013IL-23 antibodies in the treatment of inflammatory bowel disease. Gastroenterol Hepatol 15(5):255","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"1723_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T (2020) Ulcerative colitis. Nat Rev Dis Primers 6(1):1\u201320. https:\/\/doi.org\/10.1038\/s41572-020-0205-x","journal-title":"Nat Rev Dis Primers"},{"issue":"suppl_2","key":"1723_CR24","doi-asserted-by":"publisher","first-page":"S653","DOI":"10.1093\/ECCO-JCC\/JJY060","volume":"12","author":"CA Lamb","year":"2018","unstructured":"Lamb CA, O\u2019Byrne S, Keir ME, Butcher EC (2018) Gut-selective integrin-targeted therapies for inflammatory bowel disease. J Crohn\u2019s Colitis 12(suppl_2):S653\u2013S668. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJY060","journal-title":"J Crohn\u2019s Colitis"},{"issue":"5","key":"1723_CR25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","volume":"165","author":"JD Lewis","year":"2023","unstructured":"Lewis JD, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, Dawwas GK, Weiss A, Constant BD, McCauley M, Haynes K, Yang JY, Schaubel DE, Hurtado-Lorenzo A, Kappelman MD (2023) Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology 165(5):1197-1205.e2. https:\/\/doi.org\/10.1053\/j.gastro.2023.07.003","journal-title":"Gastroenterology"},{"issue":"1","key":"1723_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S43556-024-00207-W","volume":"5","author":"Y Liang","year":"2024","unstructured":"Liang Y, Li Y, Lee C, Yu Z, Chen C, Liang C (2024) Ulcerative colitis: molecular insights and intervention therapy. Mol Biomed 5(1):1\u201332. https:\/\/doi.org\/10.1186\/S43556-024-00207-W","journal-title":"Mol Biomed"},{"key":"1723_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212989","author":"S Motoya","year":"2019","unstructured":"Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T (2019) Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0212989","journal-title":"PLoS ONE"},{"issue":"4","key":"1723_CR28","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/S12328-024-01976-1\/FIGURES\/1","volume":"17","author":"N Nakamura","year":"2024","unstructured":"Nakamura N, Honzawa Y, Ohtsu T, Sano Y, Ito Y, Fukata N, Fukui T, Naganuma M (2024) Efficacy of upadacitinib in the achievement of clinical and endoscopic remission in hospitalized patients with ulcerative colitis. Clin J Gastroenterol 17(4):654\u2013657. https:\/\/doi.org\/10.1007\/S12328-024-01976-1\/FIGURES\/1","journal-title":"Clin J Gastroenterol"},{"issue":"23","key":"1723_CR29","doi-asserted-by":"publisher","first-page":"7186","DOI":"10.3390\/JCM13237186","volume":"13","author":"B Neri","year":"2024","unstructured":"Neri B, Mancone R, Fiorillo M, Schiavone SC, Migliozzi S, Biancone L (2024) Efficacy and safety of Janus kinase-inhibitors in ulcerative colitis. J Clin Med 13(23):7186. https:\/\/doi.org\/10.3390\/JCM13237186","journal-title":"J Clin Med"},{"key":"1723_CR30","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.052","author":"R Panaccione","year":"2014","unstructured":"Panaccione R, Ghosh S, Middleton S, M\u00e1rquez JR, Scott BB, Flint L, Van Hoogstraten HJF, Chen AC, Zheng H, Danese S, Rutgeerts P (2014) Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.052","journal-title":"Gastroenterology"},{"issue":"2","key":"1723_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2468-1253(21)00298-3","volume":"7","author":"L Peyrin-Biroulet","year":"2022","unstructured":"Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ (2022) Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol 7(2):128\u2013140. https:\/\/doi.org\/10.1016\/S2468-1253(21)00298-3","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1723_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ECCO-JCC\/JJAB178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, Fiorino G, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Doherty G (2022) ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohn\u2019s Colitis 16(1):2\u201317. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJAB178","journal-title":"J Crohn\u2019s Colitis"},{"issue":"6","key":"1723_CR33","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gut.2010.221127","volume":"60","author":"W Reinisch","year":"2011","unstructured":"Reinisch W, Sandborn WJ, Hommes DW, D\u2019Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R (2011) Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60(6):780\u2013787. https:\/\/doi.org\/10.1136\/gut.2010.221127","journal-title":"Gut"},{"issue":"3","key":"1723_CR34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/AJG.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD (2019) ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 114(3):384\u2013413. https:\/\/doi.org\/10.14309\/AJG.0000000000000152","journal-title":"Am J Gastroenterol"},{"key":"1723_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01927-5","author":"DT Rubin","year":"2024","unstructured":"Rubin DT, Allegretti JR, Pan\u00e9s J, Shipitofsky N, Yarandi SS, Huang K-HG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A, QUASAR Study Group (2024) Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet (London, England). https:\/\/doi.org\/10.1016\/S0140-6736(24)01927-5","journal-title":"Lancet (London, England)"},{"key":"1723_CR36","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, De Villiers WJS, Present D, Sands BE, Colombel JF (2005) Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (Vol. 8). www.nejm.org","DOI":"10.1055\/s-2005-869606"},{"key":"1723_CR37","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Van Assche G, Reinisch W, Colombel J, D\u2019Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB (2012) Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. https:\/\/doi.org\/10.1053\/j.gastro.2011.10.032","journal-title":"Gastroenterology"},{"issue":"1","key":"1723_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, J\u00e4rnerot G, Hibi T, Rutgeerts P (2014a) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146(1):85\u201395. https:\/\/doi.org\/10.1053\/j.gastro.2013.05.048","journal-title":"Gastroenterology"},{"key":"1723_CR39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.06.010","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, J\u00e4rnerot G, Rutgeerts P (2014b) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. https:\/\/doi.org\/10.1053\/j.gastro.2013.06.010","journal-title":"Gastroenterology"},{"issue":"18","key":"1723_CR40","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/nejmoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Pan\u00e9s J (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376(18):1723\u20131736. https:\/\/doi.org\/10.1056\/nejmoa1606910","journal-title":"N Engl J Med"},{"issue":"3","key":"1723_CR41","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Baert F, Danese S, Krznari\u0107 \u017d, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D\u2019Haens G, Vermeire S (2020) Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology 158(3):562-572.e12. https:\/\/doi.org\/10.1053\/j.gastro.2019.08.027","journal-title":"Gastroenterology"},{"issue":"14","key":"1723_CR42","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/nejmoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D\u2019Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel J-F, Laine L, Danese S (2021) Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med 385(14):1280\u20131291. https:\/\/doi.org\/10.1056\/nejmoa2033617","journal-title":"N Engl J Med"},{"issue":"13","key":"1723_CR43","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/nejmoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel J-F, T\u00f6r\u00fcner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S (2019a) Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 381(13):1215\u20131226. https:\/\/doi.org\/10.1056\/nejmoa1905725","journal-title":"N Engl J Med"},{"issue":"13","key":"1723_CR44","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/nejmoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C (2019b) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381(13):1201\u20131214. https:\/\/doi.org\/10.1056\/nejmoa1900750","journal-title":"N Engl J Med"},{"issue":"9","key":"1723_CR45","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S2468-1253(19)30414-5","volume":"5","author":"UN Shivaji","year":"2020","unstructured":"Shivaji UN, Nardone OM, Cannatelli R, Smith SC, Ghosh S, Iacucci M (2020) Small molecule oral targeted therapies in ulcerative colitis. Lancet Gastroenterol Hepatol 5(9):850\u2013861. https:\/\/doi.org\/10.1016\/S2468-1253(19)30414-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1723_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.GASTROHEP.2020.07.001","volume":"43","author":"B Sicilia","year":"2020","unstructured":"Sicilia B, Garc\u00eda-L\u00f3pez S, Gonz\u00e1lez-Lama Y, Zabana Y, Hinojosa J, Gomoll\u00f3n F (2020) Gu\u00eda GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodolog\u00eda GRADE. Gastroenterol Hepatol 43:1\u201357. https:\/\/doi.org\/10.1016\/J.GASTROHEP.2020.07.001","journal-title":"Gastroenterol Hepatol"},{"key":"1723_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.L4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/BMJ.L4898","journal-title":"BMJ"},{"issue":"2","key":"1723_CR48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","volume":"49","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, Mostafa NM, Chao J, Arora V, Camez A, Thakkar RB, Watanabe M (2014) Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 49(2):283\u2013294. https:\/\/doi.org\/10.1007\/s00535-013-0922-y","journal-title":"J Gastroenterol"},{"issue":"1","key":"1723_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S10787-011-0104-6\/FIGURES\/2","volume":"20","author":"S Thomas","year":"2012","unstructured":"Thomas S, Baumgart DC (2012) Targeting leukocyte migration and adhesion in Crohn\u2019s disease and ulcerative colitis. Inflammopharmacology 20(1):1\u201318. https:\/\/doi.org\/10.1007\/S10787-011-0104-6\/FIGURES\/2","journal-title":"Inflammopharmacology"},{"key":"1723_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/S41575-024-01035-7\/METRICS","author":"S Vieujean","year":"2025","unstructured":"Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, Magro F, Danese S (2025) Understanding the therapeutic toolkit for inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. https:\/\/doi.org\/10.1038\/S41575-024-01035-7\/METRICS","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"1723_CR51","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1001\/JAMA.2023.23814","volume":"331","author":"R Voelker","year":"2024","unstructured":"Voelker R (2024) What is ulcerative colitis? JAMA 331(8):716\u2013716. https:\/\/doi.org\/10.1001\/JAMA.2023.23814","journal-title":"JAMA"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01723-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:06:21Z","timestamp":1750226781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01723-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1723"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01723-z","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study is a network meta-analysis of previously published data and does not involve any new studies with human participants or animals performed by the authors. Therefore, ethical approval and informed consent were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}